ONO-2808 not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ONO-2808 will be administered to participants orally once daily for 48 weeks.”In the company’s words, NCT07825402 on ClinicalTrials.gov
- Main trialPhase 3
- “The main goal of this clinical trial is to learn if ONO-2808 works to treat adults with the Parkinsonian subtype of Multiple System Atrophy (MSA-P). Researchers will compare ONO-2808 to a placebo (a look-alike substance that contains no drug) to see if ONO-2808 works to treat MSA-P. Participants will: * Take ONO-2808 or placebo orally for up to 48 weeks * Make visits to the clinic for checkups and tests * Answer questions about their health throughout the trial.”In the company’s words, NCT07825402 on ClinicalTrials.gov
Other drugs for Multiple System Atrophy, Parkinson Variant
Coming up1
- Oct 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Oct 2029 | A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) | |
| Phase 2Active, not recruiting | 15 Sep 2025 | A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy | |
| Phase 1Completed | 26 Aug 2021 | A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026